Houston, TX – According to filings with the U.S. Securities and Exchange Commission, Memgen is raising $5,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Bob Coates played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Memgen

Memgen is a biotech company whose mission is to substantially improve cancer patient survival with our viral cancer immunotherapies.

To learn more about Memgen, visit http://memgenbio.com/

Contact:
Bob Coates, Chief Executive Officer
832-548-5651
bcoates@memgenbio.com
https://www.linkedin.com/in/bob-coates-3957203/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved